Significance of Parafibromin Expression in Laryngeal Squamous Cell Carcinomas
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Parafibromin is a product of the tumor suppressor gene that has been studied as a potential indicator of tumor aggressiveness in the parathyroid, breast, colorectum, and stomach. However, the clinical significance and potential function of parafibromin expression in head and neck squamous cell carcinomas remain largely unknown. The aim of this study was to evaluate the expression of parafibromin in laryngeal squamous cell carcinoma (LSCC) and to verify its potential as a biomarker of tumor behavior. Methods: Parafibromin expression was evaluated in 30 cases of LSCC using immunohistochemistry. The correlations between parafibromin expression and clinicopathologic parameters were investigated. Results: Parafibromin expression was positive in 15 cases (50%) and negative in 15 cases (50%). Tumor size and T stage showed a statistically significant inverse relationship with parafibromin expression (p = .028 and p < .001, respectively). Parafibromin expression was not associated with age, sex, lymph node metastasis, tumor differentiation, or tumor location. There was no statistically significant relationship between parafibromin expression and progression-free survival in the patients (p > .05). Conclusions: Our results indicate that the downregulation or loss of parafibromin expression can be employed as a novel marker of tumor progression or aggressiveness in LSCC.
Abstract
Background: Parafibromin is a product of the tumor suppressor gene that has been studied as a potential indicator of tumor aggressiveness in the parathyroid, breast, colorectum, and stomach. However, the clinical significance and potential function of parafibromin expression in head and neck squamous cell carcinomas remain largely unknown. The aim of this study was to evaluate the expression of parafibromin in laryngeal squamous cell carcinoma (LSCC) and to verify its potential as a biomarker of tumor behavior. Methods: Parafibromin expression was evaluated in 30 cases of LSCC using immunohistochemistry. The correlations between parafibromin expression and clinicopathologic parameters were investigated. Results: Parafibromin expression was positive in 15 cases (50%) and negative in 15 cases (50%). Tumor size and T stage showed a statistically significant inverse relationship with parafibromin expression (p = .028 and p < .001, respectively). Parafibromin expression was not associated with age, sex, lymph node metastasis, tumor differentiation, or tumor location. There was no statistically significant relationship between parafibromin expression and progression-free survival in the patients (p > .05). Conclusions: Our results indicate that the downregulation or loss of parafibromin expression can be employed as a novel marker of tumor progression or aggressiveness in LSCC.
참고문헌 (17)
- Genden EM, "Evolution of the management of laryngeal cance", Oral Oncol, 43, pp.431~439 (2007)
- Li L, "Expression of paxillin in laryngeal squamous cell carcinoma and its prognostic value", Int J Clin Exp Pathol, 8, pp.9232~9239 (2015)
- Marioni G, "Current opinion in diagnosis and treatment of laryngeal carcinoma", Cancer Treat Rev, 32, pp.504~515 (2006)
- Serap Karaarslan, "Parafibromin Staining Characteristics in Urothelial Carcinomas and Relationship with Prognostic Parameters", Journal of Pathology and Translational Medicine, 49(5), pp.389~395 (2015), 대한병리학회[DOI]
- Zhang Z, "The clinicopathological significances and biological functions of parafibromin expression in head and neck squamous cell carcinomas", Tumour Biol, 36, pp.9487~9497 (2015)
- Newey PJ, "Parafibromin: functional insights", J Intern Med, 266, pp.84~98 (2009)
- Carpten JD, "HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome", Nat Genet, 32, pp.676~680 (2002)
- Wang PF, "HRPT2, a tumor suppressor gene for hyperparathyroidism-jaw tumor syndrome", Horm Metab Res, 37, pp.380~383 (2005)
- Yart A, "The HRPT2 tumor suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II", Mol Cell Biol, 25, pp.5052~5060 (2005)
- Zhang C, "Parafibromin inhibits cancer cell growth and causes G1 phase arrest", Biochem Biophys Res Commun, 350, pp.17~24 (2006)
- Porzionato A, "Immunohistochemical assessment of parafibromin in mouse and human tissues", J Anat, 209, pp.817~827 (2006)
- Gill AJ, "Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias", Am J Surg Pathol, 30, pp.1140~1149 (2006)
- Selvarajan S, "Parafibromin expression in breast cancer: a novel marker for prognostication?", J Clin Pathol, 61, pp.64~67 (2008)
- Zheng HC, "Parafibromin expression is an independent prognostic factor for colorectal carcinomas", Hum Pathol, 42, pp.1089~1102 (2011)
- Zheng HC, "Downregulated parafibromin expression is a promising marker for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas", Virchows Arch, 452, pp.147~155 (2008)
- Howell VM, "HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours", J Med Genet, 40, pp.657~663 (2003)
- Licitra L, "Cancer of the larynx", Crit Rev Oncol Hematol, 47, pp.65~80 (2003)